NVS
Novartis·NYSE
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 1
Revenue Beats Expectation
Bullish Abandoned Baby
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NVS
Novartis Ag
A Swiss leading global medicines company that develops branded and generic pharmaceuticals, consmer health products, vaccines and diagnostics
Pharmaceutical
02/29/1996
05/12/2000
New York Stock Exchange
75,267
12-31
Depository Receipts (Ordinary Shares)
Lichtstrasse 35, 4056 Basel, Switzerland
Research, develop, manufacture and sell patented medicines in the fields of cancer and blood diseases
Novartis AG was incorporated on February 29, 1996 as a joint stock company under the laws of Switzerland. The company is an innovative pharmaceutical company engaged in research, development, manufacturing, distribution, marketing and sales of a wide range of pharmaceutical products. It focuses on core therapeutic areas including cardiovascular, renal and metabolic diseases, immunology, neuroscience and oncology.
Company Financials
EPS
NVS has released its 2025 Q4 earnings. EPS was reported at 2.03, versus the expected 1.97, beating expectations. The chart below visualizes how NVS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NVS has released its 2025 Q4 earnings report, with revenue of 13.86B, reflecting a YoY change of 2.23%, and net profit of 2.40B, showing a YoY change of -14.75%. The Sankey diagram below clearly presents NVS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
